Top

Published in:

01-07-2012 | Original Article

Serum adiponectin and bone mineral density in male hemodialysis patients

Authors: S. Okuno, E. Ishimura, K. Norimine, N. Tsuboniwa, S. Kagitani, K. Yamakawa, T. Yamakawa, K. K. Sato, T. Hayashi, S. Shoji, Y. Nishizawa, M. Inaba

Published in: Osteoporosis International | Issue 7/2012

Abstract

Summary

Bone mineral density of the 1/3 distal radius, ultra-distal radius, and lumbar spine correlated significantly and negatively with serum adiponectin. There was a significant positive correlation between serum adiponectin and serum NTX. Thus, adiponectin may play a role in mineral and bone disorder in chronic kidney disease stage 5 dialysis (CKD 5D) patients.

Introduction

Serum adiponectin, an adipocyte-produced hormone, has been reported to correlate negatively with bone mineral density (BMD) in the general population. However, little is known about the association between adiponectin and BMD in patients with CKD.

Methods

BMD of the 1/3 distal and ultra-distal radius, which are enriched with cortical and cancellous bone, respectively, and the lumbar spine was measured by dual X-ray absorptiometry in 114 Japanese male hemodialysis patients (age 61.0 ± 11.1 years; hemodialysis duration 6.6 ± 3.0 years; 43.9% diabetics). Serum total adiponectin, bone formation marker (bone alkaline phosphatase, BAP), and bone resorption marker (cross-linked N-telopeptide of type I collagen (NTX)) were measured.

Results

The BMD of the 1/3 distal radius, ultra-distal radius, and lumbar spine correlated significantly and negatively with serum adiponectin level (r = −0.229, p = 0.014; r = −0.286, p = 0.002; r = −0.227, p = 0.013, respectively). In multiple linear regression analyses, serum adiponectin was significantly and independently associated with the BMD of the 1/3 distal radius (R ² = 0.173, p < 0.001) and ultra-distal radius (R ² = 0.278, p < 0.001) after adjustment of age, hemodialysis duration, body weight, %fat mass, and log [intact PTH], although it was not with the BMD of the lumbar spine. There was a significant positive correlation between serum adiponectin and serum NTX (r = 0.321, p < 0.001), although there was no significant correlation between serum adiponectin and serum BAP.

Conclusion

Increased levels of serum adiponectin were associated with decrease in BMD in male hemodialysis patients. Adiponectin may play a role in mineral and bone disorder, possibly in bone resorption, of patients with CKD 5D.

Yatagai T, Nagasaka S, Taniguchi A, Fukushima M, Nakamura T, Kuroe A, Nakai Y, Ishibashi S (2003) Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism 52:1274–1278PubMedCrossRef

Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, Krakoff J (2002) Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360:57–58PubMedCrossRef

Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79–83PubMedCrossRef

Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595–1599PubMedCrossRef

Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y (1999) Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100:2473–2476PubMed

Matsuzawa Y (2010) Establishment of a concept of visceral fat syndrome and discovery of adiponectin. Proc Jpn Acad Ser B Phys Biol Sci 86:131–141PubMedCrossRef

Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y (2002) Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13:134–141PubMedCrossRef

Odamaki M, Furuya R, Kinumura Y, Ikegaya N, Kumagai H (2006) Association between plasma adiponectin concentration and visceral fat accumulation in hemodialysis patients. Nephron Clin Pract 102:c8–c13PubMedCrossRef

Ignacy W, Chudek J, Adamczak M, Funahashi T, Matsuzawa Y, Kokot F, Wiecek A (2005) Reciprocal association of plasma adiponectin and serum C-reactive protein concentration in haemodialysis patients with end-stage kidney disease–a follow-up study. Nephron Clin Pract 101:c18–c24PubMedCrossRef

10.

Menon V, Li L, Wang X, Greene T, Balakrishnan V, Madero M, Pereira AA, Beck GJ, Kusek JW, Collins AJ, Levey AS, Sarnak MJ (2006) Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 17:2599–2606PubMedCrossRef

11.

Rao M, Li L, Tighiouart H, Jaber BL, Pereira BJ, Balakrishnan VS (2008) Plasma adiponectin levels and clinical outcomes among haemodialysis patients. Nephrol Dial Transplant 23:2619–2628PubMedCrossRef

12.

Diez JJ, Estrada P, Bajo MA, Fernandez-Reyes MJ, Grande C, del Peso G, Heras M, Molina A, Iglesias P, Sanchez-Villanueva R, Selgas R (2009) High stable serum adiponectin levels are associated with a better outcome in prevalent dialysis patients. Am J Nephrol 30:244–252PubMedCrossRef

13.

Drechsler C, Krane V, Winkler K, Dekker FW, Wanner C (2009) Changes in adiponectin and the risk of sudden death, stroke, myocardial infarction, and mortality in hemodialysis patients. Kidney Int 76:567–575PubMedCrossRef

14.

Ealey KN, Kaludjerovic J, Archer MC, Ward WE (2008) Adiponectin is a negative regulator of bone mineral and bone strength in growing mice. Exp Biol Med (Maywood) 233:1546–1553CrossRef

15.

Berner HS, Lyngstadaas SP, Spahr A, Monjo M, Thommesen L, Drevon CA, Syversen U, Reseland JE (2004) Adiponectin and its receptors are expressed in bone-forming cells. Bone 35:842–849PubMedCrossRef

16.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl S1–130

17.

Nishizawa Y, Nakamura T, Ohata H, Kushida K, Gorai I, Shiraki M, Fukunaga M, Hosoi T, Miki T, Nakatsuka K, Miura M (2001) Guidelines on the use of biochemical markers of bone turnover in osteoporosis (2001). J Bone Miner Metab 19:338–344PubMedCrossRef

18.

Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J (2000) The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 11(Suppl 6):S2–S17PubMedCrossRef

19.

Maeno Y, Inaba M, Okuno S, Yamakawa T, Ishimura E, Nishizawa Y (2005) Serum concentrations of cross-linked N-telopeptides of type I collagen: new marker for bone resorption in hemodialysis patients. Clin Chem 51:2312–2317PubMedCrossRef

20.

Ueda M, Inaba M, Okuno S, Maeno Y, Ishimura E, Yamakawa T, Nishizawa Y (2005) Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH. Life Sci 77:1130–1139PubMedCrossRef

21.

Ueda M, Inaba M, Okuno S, Nagasue K, Kitatani K, Ishimura E, Shimizu M, Miki T, Kim M, Nishizawa Y (2002) Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. Am J Kidney Dis 40:802–809PubMedCrossRef

22.

Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T (2009) Relationships between serum adiponectin levels versus bone mineral density, bone metabolic markers, and vertebral fractures in type 2 diabetes mellitus. Eur J Endocrinol 160:265–273PubMedCrossRef

23.

Jurimae J, Rembel K, Jurimae T, Rehand M (2005) Adiponectin is associated with bone mineral density in perimenopausal women. Horm Metab Res 37:297–302PubMedCrossRef

24.

Lenchik L, Register TC, Hsu FC, Lohman K, Nicklas BJ, Freedman BI, Langefeld CD, Carr JJ, Bowden DW (2003) Adiponectin as a novel determinant of bone mineral density and visceral fat. Bone 33:646–651PubMedCrossRef

25.

Peng XD, Xie H, Zhao Q, Wu XP, Sun ZQ, Liao EY (2008) Relationships between serum adiponectin, leptin, resistin, visfatin levels and bone mineral density, and bone biochemical markers in Chinese men. Clin Chim Acta 387:31–35PubMedCrossRef

26.

Richards JB, Valdes AM, Burling K, Perks UC, Spector TD (2007) Serum adiponectin and bone mineral density in women. J Clin Endocrinol Metab 92:1517–1523PubMedCrossRef

27.

Huang KC, Cheng WC, Yen RF, Tsai KS, Tai TY, Yang WS (2004) Lack of independent relationship between plasma adiponectin, leptin levels and bone density in nondiabetic female adolescents. Clin Endocrinol (Oxf) 61:204–208CrossRef

28.

Jurimae J, Jurimae T (2007) Plasma adiponectin concentration in healthy pre- and postmenopausal women: relationship with body composition, bone mineral, and metabolic variables. Am J Physiol Endocrinol Metab 293:E42–E47PubMedCrossRef

29.

Oh KW, Lee WY, Rhee EJ, Baek KH, Yoon KH, Kang MI, Yun EJ, Park CY, Ihm SH, Choi MG, Yoo HJ, Park SW (2005) The relationship between serum resistin, leptin, adiponectin, ghrelin levels and bone mineral density in middle-aged men. Clin Endocrinol (Oxf) 63:131–138CrossRef

30.

Kontogianni MD, Dafni UG, Routsias JG, Skopouli FN (2004) Blood leptin and adiponectin as possible mediators of the relation between fat mass and BMD in perimenopausal women. J Bone Miner Res 19:546–551PubMedCrossRef

31.

Ozkurt B, Ozkurt ZN, Altay M, Aktekin CN, Caglayan O, Tabak Y (2009) The relationship between serum adiponectin level and anthropometry, bone mass, osteoporotic fracture risk in postmenopausal women. Eklem Hastalik Cerrahisi 20:78–84PubMed

32.

Bacchetta J, Boutroy S, Guebre-Egziabher F, Juillard L, Drai J, Pelletier S, Richard M, Charrie A, Carlier MC, Chapurlat R, Laville M, Fouque D (2009) The relationship between adipokines, osteocalcin and bone quality in chronic kidney disease. Nephrol Dial Transplant 24:3120–3125PubMedCrossRef

33.

Guideline Working Group, Japanese Society for Dialysis Therapy (2008) Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial 12:514–525CrossRef

34.

Okuno S, Inaba M, Kitatani K, Ishimura E, Yamakawa T, Nishizawa Y (2005) Serum levels of C-terminal telopeptide of type I collagen: a useful new marker of cortical bone loss in hemodialysis patients. Osteoporos Int 16:501–509PubMedCrossRef

35.

Gomez B Jr, Ardakani S, Ju J, Jenkins D, Cerelli MJ, Daniloff GY, Kung VT (1995) Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 41:1560–1566PubMed

36.

Kumeda Y, Inaba M, Tahara H, Kurioka Y, Ishikawa T, Morii H, Nishizawa Y (2000) Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism. J Clin Endocrinol Metab 85:4157–4161PubMedCrossRef

37.

Gertz BJ, Clemens JD, Holland SD, Yuan W, Greenspan S (1998) Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int 63:102–106PubMedCrossRef

38.

Clemens JD, Herrick MV, Singer FR, Eyre DR (1997) Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clin Chem 43:2058–2063PubMed

39.

Baron R (1999) Anatomy and ultrastructure of bone. In: Fravus MJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism. Lippincott Williams, Philadelphia, pp 3–10

40.

Kohno K, Inaba M, Okuno S, Maeno Y, Maekawa K, Yamakawa T, Ishimura E, Nishizawa Y (2009) Association of reduction in bone mineral density with mortality in male hemodialysis patients. Calcif Tissue Int 84:180–185PubMedCrossRef

41.

Ishimura E, Okuno S, Kim M, Yamamoto T, Izumotani T, Otoshi T, Shoji T, Inaba M, Nishizawa Y (2001) Increasing body fat mass in the first year of hemodialysis. J Am Soc Nephrol 12:1921–1926PubMed

42.

Zhao LJ, Jiang H, Papasian CJ, Maulik D, Drees B, Hamilton J, Deng HW (2008) Correlation of obesity and osteoporosis: effect of fat mass on the determination of osteoporosis. J Bone Miner Res 23:17–29PubMedCrossRef

43.

Frost M, Abrahamsen B, Nielsen TL, Frystyk J, Flyvbjerg A, Hagen C, Andersen M, Brixen K (2010) Adiponectin and peak bone mass in men: a cross-sectional, population-based study. Calcif Tissue Int 87:36–43PubMedCrossRef

44.

Oshima K, Nampei A, Matsuda M, Iwaki M, Fukuhara A, Hashimoto J, Yoshikawa H, Shimomura I (2005) Adiponectin increased bone mass by suppressing osteoclast and actiating osteoblast. Biochem Biophys Res Commun 331:520–526

45.

Luo XH, Guo LJ, Yuan LQ, Xie H, Zhou HD, Wu XP, Liao EY (2005) Adiponectin stimulates human osteoblasts proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res 309:99–109

46.

Luo XH, Guo LJ, Xie H, Yuan LQ, Wu XP, Zhou HD, Liao EY (2006) Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res 21:1648–1656

47.

Wu N, Wang QP, Li H, Wu XP, Sun ZQ, Luo XH (2010) Relationships between serum adiponectin, leptin concentrations and bone mineral density, and bone biochemical markers in Chinese women. Clin Chim Acta 411:771–775

48.

Wolf G (2003) Adiponectin: a regulator of energy homeostasis. Nutr Rev 61:290–292

49.

Oh DK, Ciaraldi T, Henry RR (2007) Adiponectin in health and disease. Diabetes Obes metab 9:282–289

50.

Araneta MR, von Muhlen D, Barrett-Connor E (2009) Sex differences in the association between adiponectin and BMD, bone loss, and fractures: the Rancho Bernardo study. J Bone Miner Res 24:2016–2022PubMedCrossRef

Title: Serum adiponectin and bone mineral density in male hemodialysis patients
Authors: S. Okuno
E. Ishimura
K. Norimine
N. Tsuboniwa
S. Kagitani
K. Yamakawa
T. Yamakawa
K. K. Sato
T. Hayashi
S. Shoji
Y. Nishizawa
M. Inaba
Publication date: 01-07-2012
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 7/2012
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-011-1789-5

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Serum adiponectin and bone mineral density in male hemodialysis patients

Abstract

Summary

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2012

Association of CDX1 binding site of periostin gene with bone mineral density and vertebral fracture risk

In Memoriam: Philip Neil Sambrook

Relationship between calcaneal quantitative ultrasound and hip dual energy X-ray absorptiometry in young healthy men

Risk factors for osteoporosis in long-term survivors of intracranial germ cell tumors

Frailty and sarcopenia: definitions and outcome parameters

Mortality after vertebral fracture in Korea